Oligonucleotide-based strategies to combat polyglutamine diseases

Nucleic Acids Research

Volumn 42, Issue 11, 2014, Pages 6787-6810

  Fiszer, Agnieszka ^a   Krzyzosiak, Wlodzimierz J ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BENZIMIDAZOLE DERIVATIVE; HUNTINGTIN; INTERFERON; SMALL INTERFERING RNA;

ALLELE; ANTISENSE THERAPY; AR GENE; ARTICLE; ATN1 GENE; ATXN1 GENE; ATXN2 GENE; ATXN3 GENE; ATXN7 GENE; AUTOSOMAL DOMINANT DISORDER; CACNA1A GENE; CAG REPEAT; CHEMICAL MODIFICATION; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DMPK GENE; GENE; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC VARIABILITY; GENOTOXICITY; HTT GENE; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; NONHUMAN; POLYGLUTAMINE DISEASE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPINOCEREBELLAR ATAXIA TYPE 1; SPINOCEREBELLAR ATAXIA TYPE 17; SPINOCEREBELLAR ATAXIA TYPE 2; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR ATAXIA TYPE 6; SPINOCEREBELLAR ATAXIA TYPE 7; SPINOCEREBELLAR DEGENERATION; TBP GENE;

ANIMALS; GENETIC DISEASES, INBORN; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; RNA INTERFERENCE; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84903168540     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gku385     Document Type: Article

References (306)

1. Orr, H.T. and Zoghbi, H.Y. (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci., 30, 575-621.
2. Moseley, M.L., Zu, T., Ikeda, Y., Gao, W., Mosemiller, A.K., Daughters, R.S., Chen, G., Weatherspoon, M.R., Clark, H.B., Ebner, T.J. et al. (2006) Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet., 38, 758-769.
3. Sharp, A.H., Loev, S.J., Schilling, G., Li, S.-H., Li, X.-J., Bao, J., Wagster, M. V, Kotzuk, J.A., Steiner, J.P., Lo, A. et al. (1995) Widespread expression of Huntington's disease gene (IT15) protein product. Neuron, 14, 1065-1074.
4. Riley, B.E. and Orr, H.T. (2006) Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. Genes Dev., 20, 2183-2192.
5. Williams, A.J. and Paulson, H.L. (2008) Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci., 31, 521-528.
6. Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537-548.
7. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
8. Donaldson, K.M., Li, W., Ching, K.A., Batalov, S., Tsai, C.C. and Joazeiro, C.A. (2003) Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc. Natl. Acad. Sci. U.S.A., 100, 8892-8897.
9. Yamada, M., Sato, T., Tsuji, S. and Takahashi, H. (2008) CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol., 115, 71-86.
10. Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell, 95, 55-66.
11. Huynh, D.P., Figueroa, K., Hoang, N. and Pulst, S.M. (2000) Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat. Genet., 26, 44-50.
12. Tarlac, V., Turnbull, V., Stefani, D., Kelly, L., Walsh, R. and Storey, E. (2007) Inclusion formation by ataxins-1,-2,-3, and-7. Int. J. Neurosci., 117, 1289-1314.
13. Graham, R.K., Deng, Y., Slow, E.J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z. et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 125, 1179-1191.
14. Wellington, C.L., Ellerby, L.M., Hackam, A.S., Margolis, R.L., Trifiro, M.A., Singaraja, R., McCutcheon, K., Salvesen, G.S., Propp, S.S., Bromm, M. et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem., 273, 9158-9167.
15. Kordasiewicz, H.B., Thompson, R.M., Clark, H.B. and Gomez, C.M. (2006) C-termini of P/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Hum. Mol. Genet., 15, 1587-1599.
16. Young, J.E., Gouw, L., Propp, S., Sopher, B.L., Taylor, J., Lin, A., Hermel, E., Logvinova, A., Chen, S.F., Chen, S. et al. (2007) Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J. Biol. Chem., 282, 30150-30160.
17. Pouladi, M.A., Morton, A.J. and Hayden, M.R. (2013) Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci., 14, 708-721.
18. Pennuto, M., Palazzolo, I. and Poletti, A. (2009) Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum. Mol. Genet., 18, R40-R47.
19. Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell, 2, 831-837.
20. Chen, H.K., Fernandez-Funez, P., Acevedo, S.F., Lam, Y.C., Kaytor, M.D., Fernandez, M.H., Aitken, A., Skoulakis, E.M., Orr, H.T., Botas, J. et al. (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell, 113, 457-468.
21. De Chiara, C., Menon, R.P., Strom, M., Gibson, T.J. and Pastore, A. (2009) Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factors. PLoS One, 4, e8372.
22. Orr, H.T. (2012) SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis. Prog. Neurobiol., 99, 179-85.
23. Orr, H.T. (2012) Polyglutamine neurodegeneration: expanded glutamines enhance native functions. Curr. Opin. Genet. Dev., 22, 251-255.
24. Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G.P., Davies, S.W., Lehrach, H. and Wanker, E.E. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 90, 549-558.
25. Poirier, M.A., Jiang, H. and Ross, C.A. (2005) A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum. Mol. Genet., 14, 765-774.
26. Nagai, Y., Inui, T., Popiel, H.A., Fujikake, N., Hasegawa, K., Urade, Y., Goto, Y., Naiki, H. and Toda, T. (2007) A toxic monomeric conformer of the polyglutamine protein.Nat. Struct. Mol. Biol., 14, 332-340.
27. Fiumara, F., Fioriti, L., Kandel, E.R. and Hendrickson, W.A. (2010) Essential role of coiled coils for aggregation and activity of Q/N-rich prions and PolyQ proteins. Cell, 143, 1121-1135.
28. Petrakis, S., Schaefer, M.H., Wanker, E.E. and Andrade-Navarro, M.A. (2013) Aggregation of polyQ-extended proteins is promoted by interaction with their natural coiled-coil partners. Bioessays, 35, 503-507.
29. Bae, B.-I., Hara, M.R., Cascio, M.B., Wellington, C.L., Hayden, M.R., Ross, C.A., Ha, H.C., Li, X.-J., Snyder, S.H. and Sawa, A. (2006) Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proc. Natl. Acad. Sci. U.S.A., 103, 3405-3409.
30. Kaltenbach, L.S., Romero, E., Becklin, R.R., Chettier, R., Bell, R., Phansalkar, A., Strand, A., Torcassi, C., Savage, J., Hurlburt, A. et al. (2007) Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet., 3, e82.
31. Savas, J.N., Makusky, A., Ottosen, S., Baillat, D., Then, F., Krainc, D., Shiekhattar, R., Markey, S.P. and Tanese, N. (2008) Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc. Natl. Acad. Sci. U.S.A., 105, 10820-10825.
32. Ratovitski, T., Chighladze, E., Arbez, N., Boronina, T., Herbrich, S., Cole, R.N. and Ross, C.A. (2012) Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle, 11, 2006-2021.
33. Serra, H.G., Duvick, L., Zu, T., Carlson, K., Stevens, S., Jorgensen, N., Lysholm, A., Burright, E., Zoghbi, H.Y., Clark, H.B. et al. (2006) ROR-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell, 127, 697-708.
34. Lam, Y.C., Bowman, A.B., Jafar-Nejad, P., Lim, J., Richman, R., Fryer, J.D., Hyun, E.D., Duvick, L.A., Orr, H.T., Botas, J. et al. (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell, 127, 1335-1347.
35. Palhan, V.B., Chen, S., Peng, G.-H., Tjernberg, A., Gamper, A.M., Fan, Y., Chait, B.T., La Spada, A.R. and Roeder, R.G. (2005) Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc. Natl. Acad. Sci. U.S.A., 102, 8472-8477.
36. Helmlinger, D., Hardy, S., Abou-Sleymane, G., Eberlin, A., Bowman, A.B., Gansm̈ uller, A., Picaud, S., Zoghbi, H.Y., Trottier, Y., Tora, L. et al. (2006) Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol., 4, e67.
37. Toulouse, A., Au-Yeung, F., Gaspar, C., Roussel, J., Dion, P. and Rouleau, G.A. (2005) Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts. Hum. Mol. Genet., 14, 2649-2660.
38. Davies, J.E. and Rubinsztein, D.C. (2006) Polyalanine and polyserine frameshift products in Huntington's disease. J. Med. Genet., 43, 893-896.
39. Stochmanski, S.J., Therrien, M., Laganiere, J., Rochefort, D., Laurent, S., Karemera, L., Gaudet, R., Vyboh, K., Van Meyel, D.J., Di Cristo, G. et al. (2012) Expanded ATXN3 frameshifting events are toxic in Drosophila and mammalian neuron models. Hum. Mol. Genet., 21, 2211-2218.
40. Zu, T., Gibbens, B., Doty, N.S., Gomes-Pereira, M., Huguet, A., Stone, M.D., Margolis, J., Peterson, M., Markowski, T.W., Ingram, M.A. et al. (2011) Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. U.S.A., 108, 260-265.
41. Cleary, J.D. and Ranum, L.P. (2013) Repeat-associated non-ATG (RAN) translation in neurological disease. Hum. Mol. Genet., 22, R45-R51.
42. Sobczak, K., de Mezer, M., Michlewski, G., Krol, J. and Krzyzosiak, W.J. (2003) RNA structure of trinucleotide repeats associated with human neurological diseases. Nucleic Acids Res., 31, 5469-5482.
43. Michlewski, G. and Krzyzosiak, W.J. (2004) Molecular architecture of CAG repeats in human disease related transcripts. J. Mol. Biol., 340, 665-679.
44. Sobczak, K. and Krzyzosiak, W.J. (2004) Patterns of CAG repeat interruptions in SCA1 and SCA2 genes in relation to repeat instability. Hum. Mutat., 24, 236-247.
45. Sobczak, K. and Krzyzosiak, W.J. (2004) Imperfect CAG repeats form diverse structures in SCA1 transcripts. J. Biol. Chem., 279, 41563-41572.
46. Sobczak, K., Michlewski, G., de Mezer, M., Kierzek, E., Krol, J., Olejniczak, M., Kierzek, R. and Krzyzosiak, W.J. (2010) Structural diversity of triplet repeat RNAs. J. Biol. Chem., 285, 12755-12764.
47. De Mezer, M., Wojciechowska, M., Napierala, M., Sobczak, K. and Krzyzosiak, W.J. (2011) Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res., 39, 3852-3863.
48. Napierala, M. and Krzyzosiak, W.J. (1997) CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins. J. Biol. Chem., 272, 31079-31085.
49. Miller, J.W., Urbinati, C.R., Teng-Umnuay, P., Stenberg, M.G., Byrne, B.J., Thornton, C.A. and Swanson, M.S. (2000) Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J., 19, 4439-4448.
50. Brook, J.D., McCurrach, M.E., Harley, H.G., Buckler, A.J., Church, D., Aburatani, H., Hunter, K., Stanton, V.P., Thirion, J.P., Hudson, T. et al. (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell, 69, 799-808.
51. Wojciechowska, M. and Krzyzosiak, W.J. (2011) Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum. Mol. Genet., 20, 3811-3821.
52. Mykowska, A., Sobczak, K., Wojciechowska, M., Kozlowski, P. and Krzyzosiak, W.J. (2011) CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res., 39, 8938-8951.
53. Fiszer, A. and Krzyzosiak, W.J. (2013) RNA toxicity in polyglutamine disorders: concepts, models, and progress of research. J. Mol. Med. (Berlin)., 91, 683-691.
54. McLeod, C.J., O'Keefe, L.V. and Richards, R.I. (2005) The pathogenic agent in Drosophila models of "polyglutamine" diseases. Hum. Mol. Genet., 14, 1041-1048.
55. Li, L.-B., Yu, Z., Teng, X. and Bonini, N.M. (2008) RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature, 453, 1107-1111.
56. Shieh, S.Y. and Bonini, N.M. (2011) Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila. Hum. Mol. Genet., 20, 4810-4821.
57. Sobczak, K. and Krzyzosiak, W.J. (2005) CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. J. Biol. Chem., 280, 3898-3910.
58. Hsu, R.J., Hsiao, K.M., Lin, M.J., Li, C.Y., Wang, L.C., Chen, L.K. and Pan, H. (2011) Long tract of untranslated CAG repeats is deleterious in transgenic mice. PLoS One, 6, e16417.
59. Pouladi, M.A., Stanek, L.M., Xie, Y., Franciosi, S., Southwell, A.L., Deng, Y., Butland, S., Zhang, W., Cheng, S.H., Shihabuddin, L.S. et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet., 21, 2219-2232.
60. Tsoi, H., Lau, C.K., Lau, K.F. and Chan, H.Y.E. (2011) Perturbation of U2AF65/NXF1-mediated RNA nuclear export enhances RNA toxicity in polyQ diseases. Hum. Mol. Genet., 20, 3787-3797.
61. Tsoi, H., Lau, T.C., Tsang, S.Y., Lau, K.F. and Chan, H.Y. (2012) CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. Natl. Acad. Sci. U.S.A., 109, 13428-13433.
62. Laurent, F.X., Sureau, A., Klein, A.F., Trouslard, F., Gasnier, E., Furling, D. and Marie, J. (2012) New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats. Nucleic Acids Res., 40, 3159-3171.
63. Sathasivam, K., Neueder, A., Gipson, T.A., Landles, C., Benjamin, A.C., Bondulich, M.K., Smith, D.L., Faull, R.L., Roos, R.A., Howland, D. et al. (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. U.S.A., 110, 2366-2370.
64. Chung, D.W., Rudnicki, D.D., Yu, L. and Margolis, R.L. (2011) A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum. Mol. Genet., 20, 3467-3477.
65. Krol, J., Fiszer, A., Mykowska, A., Sobczak, K., de Mezer, M. and Krzyzosiak, W.J. (2007) Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol. Cell, 25, 575-586.
66. Mateu-Huertas, E., Porta, S., Mart́?, E., Pantano, L., Guzḿan, M., Estivill, X., Bañez-Coronel, M., Kagerbauer, B. and Ferrer, I. (2012) A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet., 8, e1002481.
67. Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66.
68. Zu, T., Duvick, L.A., Kaytor, M.D., Berlinger, M.S., Zoghbi, H.Y., Clark, H.B. and Orr, H.T. (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci., 24, 8853-8861.
69. Ŕegulier, E., Trottier, Y., Perrin, V., Aebischer, P. and D́eglon, N. (2003) Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum. Mol. Genet., 12, 2827-2836.
70. D́az-Herńandez, M., Torres-Peraza, J., Salvatori-Abarca, A., Moŕan, M.A., Ǵomez-Ramos, P., Alberch, J. and Lucas, J.J. (2005) Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J. Neurosci., 25, 9773-9781.
71. Klug, A. (2010) The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu. Rev. Biochem., 79, 213-231.
72. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. and Gregory, P.D. (2010) Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet., 11, 636-646.
73. Perez-Pinera, P., Gersbach, C.a. and Ousterout, D.G. (2012) Advances in targeted genome editing. Curr. Opin. Chem. Biol., 16, 268-277.
74. Rebar, E.J., Huang, Y., Hickey, R., Nath, A.K., Meoli, D., Nath, S., Chen, B., Xu, L., Liang, Y., Jamieson, A.C. et al. (2002) Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med., 8, 1427-1432.
75. Urnov, F.D., Miller, J.C., Lee, Y.L., Beausejour, C.M., Rock, J.M., Augustus, S., Jamieson, A.C., Porteus, M.H., Gregory, P.D. and Holmes, M.C. (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature, 435, 646-651.
76. Zou, J., Sweeney, C.L., Chou, B.K., Choi, U., Pan, J., Wang, H., Dowey, S.N., Cheng, L., Malech, H.L. et al. (2011) Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood, 117, 5561-5572.
77. Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D.E., Zhang, L., Kuball, J. et al. (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med., 18, 807-815.
78. Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S.Y., Bhagwat, A.S., Malani, N., Anguela, X.M., Sharma, R., Ivanciu, L. et al. (2011) In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature, 475, 217-221.
79. Perez, E.E., Wang, J., Miller, J.C., Jouvenot, Y., Kim, K.A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V, Lee, Y.-L. et al. (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol., 26, 808-816.
80. Mittelman, D., Moye, C., Morton, J., Sykoudis, K., Lin, Y., Carroll, D. and Wilson, J.H. (2009) Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc. Natl. Acad. Sci. U.S.A., 106, 9607-9612.
81. Garriga-Canut, M., Agustin-Pavon, C., Herrmann, F., Sanchez, A., Dierssen, M., Fillat, C. and Isalan, M. (2012) Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc. Natl. Acad. Sci. U.S.A., 109, E3136-E3145.
82. Morris, K. V, Chan, S.W., Jacobsen, S.E. and Looney, D.J. (2004) Small interfering RNA-induced transcriptional gene silencing in human cells. Science, 305, 1289-1292.
83. Janowski, B.A., Kaihatsu, K., Huffman, K.E., Schwartz, J.C., Ram, R., Hardy, D., Mendelson, C.R. and Corey, D.R. (2005) Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids. Nat. Chem. Biol., 1, 210-215.
84. Hawkins, P.G., Santoso, S., Adams, C., Anest, V. and Morris, K.V. (2009) Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells. Nucleic Acids Res., 37, 2984-2995.
85. Janowski, B.A., Huffman, K.E., Schwartz, J.C., Ram, R., Hardy, D., Shames, D.S., Minna, J.D. and Corey, D.R. (2005) Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat. Chem. Biol., 1, 216-222.
86. Robb, G.B., Brown, K.M., Khurana, J. and Rana, T.M. (2005) Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol., 12, 133-137.
87. Huang, V. and Li, L.-C. (2012) miRNA goes nuclear. RNA Biol., 9, 269-273.
88. Gagnon, K.T. and Corey, D.R. (2012) Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression. Nucleic Acid Ther., 22, 3-16.
89. Gagnon, K.T., Li, L., Chu, Y., Janowski, B.A. and Corey, D.R. (2014) RNAi factors are present and active in human cell nuclei. Cell Rep., 6, 211-221.
90. Kim, D.H., Villeneuve, L.M., Morris, K.V. and Rossi, J.J. (2006) Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat. Struct. Mol. Biol., 13, 793-797.
91. Janowski, B.A., Huffman, K.E., Schwartz, J.C., Ram, R., Nordsell, R., Shames, D.S., Minna, J.D. and Corey, D.R. (2006) Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat. Struct. Mol. Biol., 13, 787-792.
92. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
93. Sibley, C.R., Seow, Y. and Wood, M.J. (2010) Novel RNA-based strategies for therapeutic gene silencing. Mol. Ther., 18, 466-476.
94. Kole, R., Krainer, A.R. and Altman, S. (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov., 11, 125-140.
95. Liu, J., Hu, J. and Corey, D.R. (2012) Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. Nucleic Acids Res., 40, 1240-1250.
96. Prakash, T.P., Bennett, C.F., Rigo, F., Chun, S.J., Krainer, A.R. and Hua, Y. (2012) Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat. Chem. Biol., 8, 555-561.
97. Van Ommen, G.-J.B. and Aartsma-Rus, A. (2013) Advances in therapeutic RNA-targeting. N. Biotechnol., 30, 299-301.
98. Evers, M.M., Tran, H.D., Zalachoras, I., Pepers, B.A., Meijer, O.C., den Dunnen, J.T., van Ommen, G.J., Aartsma-Rus, A. and van Roon-Mom, W.M. (2013) Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiol. Dis., 58C, 49-56.
99. Evers, M.M., Tran, H.-D., Zalachoras, I., Meijer, O.C., den Dunnen, J.T., van Ommen, G.-J.B., Aartsma-Rus, A. and van Roon-Mom, W.M.C. (2013) Preventing formation of toxic N-terminal Huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Ther., 24, 4-12.
100. Mart́nez, T., Wright, N., Ĺopez-Fraga, M., Jiḿenez, A.I. and Pañeda, C. (2013) Silencing human genetic diseases with oligonucleotide-based therapies. Hum. Genet., 132, 481-493.
101. Cerritelli, S.M. and Crouch, R.J. (2009) Ribonuclease H: the enzymes in eukaryotes. FEBS J., 276, 1494-1505.
102. Lima, W.F., Wu, H., Nichols, J.G., Prakash, T.P., Ravikumar, V. and Crooke, S.T. (2003) Human RNase H1 uses one tryptophan and two lysines to position the enzyme at the 3'-DNA/5'-RNA terminus of the heteroduplex substrate. J. Biol. Chem., 278, 49860-49867.
103. Lima, W.F., Nichols, J.G., Wu, H., Prakash, T.P., Migawa, M.T., Wyrzykiewicz, T.K., Bhat, B. and Crooke, S.T. (2004) Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem., 279, 36317-36326.
104. Wu, H., Lima, W.F., Zhang, H., Fan, A., Sun, H. and Crooke, S.T. (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 279, 17181-17189.
105. Bernstein, E., Caudy, A.A., Hammond, S.M. and Hannon, G.J. (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409, 363-366.
106. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
107. Friedman, R.C., Farh, K.K.-H., Burge, C.B. and Bartel, D.P. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res., 19, 92-105.
108. Chendrimada, T.P., Gregory, R.I., Kumaraswamy, E., Norman, J., Cooch, N., Nishikura, K. and Shiekhattar, R. (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature, 436, 740-744.
109. Gregory, R.I., Chendrimada, T.P., Cooch, N. and Shiekhattar, R. (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell, 123, 631-640.
110. Elbashir, S.M., Lendeckel, W. and Tuschl, T. (2001) RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev., 15, 188-200.
111. Guo, H., Ingolia, N.T., Weissman, J.S. and Bartel, D.P. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 466, 835-840.
112. Fabian, M.R., Sonenberg, N. and Filipowicz, W. (2010) Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem., 79, 351-379.
113. Stroynowska-Czerwinska, A., Fiszer, A. and Krzyzosiak, W.J. (2014) The panorama of miRNA-mediated mechanisms in mammalian cells. Cell. Mol. Life Sci., 10.1007/s00018-013-1551-6.
114. Baker, B.F., Lot, S.S., Condon, T.P., Cheng-Flournoy, S., Lesnik, E.A., Sasmor, H.M. and Bennett, C.F. (1997) 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem., 272, 11994-12000.
115. Paessler, S., Rijnbrand, R., Stein, D.A., Ni, H., Yun, N.E., Dziuba, N., Borisevich, V., Seregin, A., Ma, Y., Blouch, R. et al. (2008) Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology, 376, 357-370.
116. Wheeler, T.M., Sobczak, K., Lueck, J.D., Osborne, R.J., Lin, X., Dirksen, R.T. and Thornton, C.a. (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science, 325, 336-339.
117. Mulders, S.A., van den Broek, W.J., Wheeler, T.M., Croes, H.J., van Kuik-Romeijn, P., de Kimpe, S.J., Furling, D., Platenburg, G.J., Gourdon, G., Thornton, C.A. et al. (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl. Acad. Sci. U.S.A., 106, 13915-13920.
118. Nakamori, M., Gourdon, G. and Thornton, C.A. (2011) Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol. Ther., 19, 2222-2227.
119. Disney, M.D. (2013) Rational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts. Drug Discov. Today.18 1228-1236
120. Gareiss, P.C., Sobczak, K., McNaughton, B.R., Palde, P.B., Thornton, C.A. and Miller, B.L. (2008) Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J. Am. Chem. Soc., 130, 16254-16261.
121. Arambula, J.F., Ramisetty, S.R., Baranger, A.M. and Zimmerman, S.C. (2009) A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc. Natl. Acad. Sci. U.S.A., 106, 16068-16073.
122. Lee, M.M., Childs-Disney, J.L., Pushechnikov, A., French, J.M., Sobczak, K., Thornton, C.A. and Disney, M.D. (2009) Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. J. Am. Chem. Soc., 131, 17464-17472.
123. Disney, M.D., Lee, M.M., Pushechnikov, A. and Childs-Disney, J.L. (2010) The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies. Chembiochem, 11, 375-382.
124. Warf, M.B., Nakamori, M., Matthys, C.M., Thornton, C.A. and Berglund, J.A. (2009) Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc. Natl. Acad. Sci. U.S.A., 106, 18551-18556.
125. Garcia-Lopez, A., Llamusi, B., Orzaez, M., Perez-Paya, E. and Artero, R.D. (2011) In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc. Natl. Acad. Sci. U.S.A., 108, 11866-11871.
126. Pushechnikov, A., Lee, M.M., Childs-Disney, J.L., Sobczak, K., French, J.M., Thornton, C.A. and Disney, M.D. (2009) Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J. Am. Chem. Soc., 131, 9767-9779.
127. Kiliszek, A., Kierzek, R., Krzyzosiak, W.J. and Rypniewski, W. (2009) Structural insights into CUG repeats containing the "stretched U-U wobble": implications for myotonic dystrophy. Nucleic Acids Res., 37, 4149-4156.
128. Kiliszek, A., Kierzek, R., Krzyzosiak, W.J. and Rypniewski, W. (2010) Atomic resolution structure of CAG RNA repeats: structural insights and implications for the trinucleotide repeat expansion diseases. Nucleic Acids Res., 38, 8370-8376.
129. Kumar, A., Park, H., Fang, P., Parkesh, R., Guo, M., Nettles, K.W. and Disney, M.D. (2011) Myotonic dystrophy type 1 RNA crystal structures reveal heterogeneous 1 1 nucleotide UU internal loop conformations. Biochemistry, 50, 9928-9935.
130. Yildirim, I., Park, H., Disney, M.D. and Schatz, G.C. (2013) A dynamic structural model of expanded RNA CAG repeats: a refined X-ray structure and computational investigations using molecular dynamics and umbrella sampling simulations. J. Am. Chem. Soc., 135, 3528-3538.
131. Lee, M.M., Pushechnikov, A. and Disney, M.D. (2009) Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chem. Biol., 4, 345-355.
132. Kumar, A., Parkesh, R., Sznajder, L.J., Childs-Disney, J.L., Sobczak, K. and Disney, M.D. (2012) Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. ACS Chem. Biol., 7, 496-505.
133. Liu, C.R., Chang, C.R., Chern, Y., Wang, T.H., Hsieh, W.C., Shen, W.C., Chang, C.Y., Chu, I.C., Deng, N., Cohen, S.N. et al. (2012) Spt4 is selectively required for transcription of extended trinucleotide repeats. Cell, 148, 690-701.
134. Krauss, S., Griesche, N., Jastrzebska, E., Chen, C., Rutschow, D., Achmuller, C., Dorn, S., Boesch, S.M., Lalowski, M., Wanker, E. et al. (2013) Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex. Nat. Commun., 4, doi:10.1038/ncomms2514.
135. Appl, T., Kaltenbach, L., Lo, D.C. and Terstappen, G.C. (2012) Targeting mutant huntingtin for the development of disease-modifying therapy. Drug Discov. Today, 17, 1217-1223.
136. Gabibov, A., Skulachev, V., Wieland, F., Just, W., Margulis, B.A., Vigont, V., Lazarev, V.F., Kaznacheyeva, E. V. and Guzhova, I. V. (2013) Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors. FEBS Lett., 587, 1997-2007.
137. Chai, Y., Koppenhafer, S.L., Bonini, N.M. and Paulson, H.L. (1999) Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci., 19, 10338-10347.
138. Pollitt, S.K., Pallos, J., Shao, J., Desai, U.A., Ma, A.A., Thompson, L.M., Marsh, J.L. and Diamond, M.I. (2003) A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron, 40, 685-694.
139. Desai, U.A., Pallos, J., Ma, A.A., Stockwell, B.R., Thompson, L.M., Marsh, J.L. and Diamond, M.I. (2006) Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet., 15, 2114-2124.
140. Bauer, P.O., Hudec, R., Goswami, A., Kurosawa, M., Matsumoto, G., Mikoshiba, K. and Nukina, N. (2012) ROCK-phosphorylated vimentin modifies mutant huntingtin aggregation via sequestration of IRBIT. Mol. Neurodegener., 7, doi:10.1186/1750-1326-7-43.
141. Fecke, W., Gianfriddo, M., Gaviraghi, G., Terstappen, G.C. and Heitz, F. (2009) Small molecule drug discovery for Huntington's disease. Drug Discov. Today, 14, 453-64.
142. Wong, H.K., Bauer, P.O., Kurosawa, M., Goswami, A., Washizu, C., Machida, Y., Tosaki, A., Yamada, M., Knopfel, T., Nakamura, T. et al. (2008) Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum. Mol. Genet., 17, 3223-3235.
143. Sarkar, S., Perlstein, E.O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R.L., Webster, J.A., Lewis, T.A., O'Kane, C.J., Schreiber, S.L. et al. (2007) Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol., 3, 331-338.
144. Bauer, P.O., Goswami, A., Wong, H.K., Okuno, M., Kurosawa, M., Yamada, M., Miyazaki, H., Matsumoto, G., Kino, Y., Nagai, Y. et al. (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat. Biotechnol., 28, 256-263.
145. Lu, B., Al-Ramahi, I., Valencia, A., Wang, Q., Berenshteyn, F., Yang, H., Gallego-Flores, T., Ichcho, S., Lacoste, A., Hild, M. et al. (2013) Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Nat. Neurosci., 16, 562-70.
146. De Chiara, C., Menon, R.P., Kelly, G. and Pastore, A. (2013) Protein-protein interactions as a strategy towards protein-specific drug design: the example of ataxin-1. PLoS One, 8, e76456.
147. De Chiara, C. and Pastore, A. (2014) Kaleidoscopic protein-protein interactions in the life and death of ataxin-1: new strategies against protein aggregation. Trends Neurosci., 37, 211-218.
148. Bowman, A.B., Lam, Y.C., Jafar-Nejad, P., Chen, H.K., Richman, R., Samaco, R.C., Fryer, J.D., Kahle, J.J., Orr, H.T. and Zoghbi, H.Y. (2007) Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat. Genet., 39, 373-379.
149. Keiser, M.S., Geoghegan, J.C., Boudreau, R.L., Lennox, K.A. and Davidson, B.L. (2013) RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol. Dis., 56, 6-13.
150. Bauer, P.O. and Nukina, N. (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem., 110, 1737-1765.
151. Zuccato, C., Valenza, M. and Cattaneo, E. (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev., 90, 905-981.
152. Ross, C.a. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
153. Switonski, P.M., Szlachcic, W.J., Gabka, A., Krzyzosiak, W.J. and Figiel, M. (2012) Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol. Neurobiol., 46, 430-466.
154. Kaplan, A. and Stockwell, B.R. (2012) Therapeutic approaches to
155. Dragatsis, I., Levine, M.S. and Zeitlin, S. (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet., 26, 300-306.
156. Reiner, A., Del Mar, N., Meade, C.A., Yang, H., Dragatsis, I., Zeitlin, S. and Goldowitz, D. (2001) Neurons lacking huntingtin differentially colonize brain and survive in chimeric mice. J. Neurosci., 21, 7608-7619.
157. Warrick, J.M., Morabito, L.M., Bilen, J., Gordesky-Gold, B., Faust, L.Z., Paulson, H.L. and Bonini, N.M. (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell, 18, 37-48.
158. Van Raamsdonk, J.M., Pearson, J., Rogers, D.A., Bissada, N., Vogl, A.W., Hayden, M.R. and Leavitt, B.R. (2005) Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 14, 1379-1392.
159. Lang, A.E., Rogaeva, E.A., Tsuda, T., Hutterer, J. and St George-Hyslop, P. (1994) Homozygous inheritance of the Machado-Joseph disease gene. Ann. Neurol., 36, 443-447.
160. Squitieri, F., Gellera, C., Cannella, M., Mariotti, C., Cislaghi, G., Rubinsztein, D.C., Almqvist, E.W., Turner, D., Bachoud-Ĺevi, A.-C., Simpson, S.A. et al. (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain, 126, 946-955.
161. Alves, S., Nascimento-Ferreira, I., Dufour, N., Hassig, R., Auregan, G., Nobrega, C., Brouillet, E., Hantraye, P., Pedroso de Lima, M.C., Deglon, N. et al. (2010) Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3 Hum. Mol. Genet., 19, 2380-2394.
162. Xia, H., Mao, Q., Eliason, S.L., Harper, S.Q., Martins, I.H., Orr, H.T., Paulson, H.L., Yang, L., Kotin, R.M. and Davidson, B.L. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med., 10, 816-820.
163. Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I.H., Mao, Q., Yang, L., Kotin, R.M., Paulson, H.L. and Davidson, B.L. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U.S.A., 102, 5820-5825.
164. Rodriguez-Lebron, E., Denovan-Wright, E.M., Nash, K., Lewin, A.S. and Mandel, R.J. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther., 12, 618-633.
165. Huang, B., Schiefer, J., Sass, C., Landwehrmeyer, G.B., Kosinski, C.M. and Kochanek, S. (2007) High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum. Gene Ther., 18, 303-311.
166. Boudreau, R.L., McBride, J.L., Martins, I., Shen, S., Xing, Y., Carter, B.J. and Davidson, B.L. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther., 17, 1053-1063.
167. Wang, Y.L., Liu, W., Wada, E., Murata, M., Wada, K. and Kanazawa, I. (2005) Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res., 53, 241-249.
168. DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R.K., Rajeev, K.G. et al. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U.S.A., 104, 17204-17209.
169. Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E. V, Mazur, C., McAlonis, M.M., Pytel, K.A., Artates, J.W., Weiss, A., Cheng, S.H., Shihabuddin, L.S. et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74, 1031-1044.
170. Do Carmo Costa, M., Luna-Cancalon, K., Fischer, S., Ashraf, N.S., Ouyang, M., Dharia, R.M., Martin-Fishman, L., Yang, Y., Shakkottai, V.G., Davidson, B.L. et al. (2013) Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol. Ther., 21, 1898-1908.
171. Rodriguez-Lebron, E., do Carmo Costa, M., Molina-Luna, K., Peron, T.M., Fischer, S., Boudreau, R.L., Davidson, B.L. and Paulson, H.L. (2013) Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol. Ther., 21, 1909-1918.
172. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi-Carter, R., Hantraye, P. et al. (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol., 65, 276-285.
173. Stanek, L.M., Sardi, S.P., Mastis, B.M., Richards, A.R., Treleaven, C.M., Taksir, T. V, Misra, K., Cheng, S.H. and Shihabuddin, L.S. (2014) Silencing mutant huntingtin by AAV-mediated RNAi ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum. Gene Ther., 10.1089/hum.2013.200.
174. McBride, J.L., Pitzer, M.R., Boudreau, R.L., Dufour, B., Hobbs, T., Ojeda, S.R. and Davidson, B.L. (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol. Ther., 19, 2152-2162.
175. Stiles, D., Zhang, Z., Ge, P., Nelson, B., Grondin, R., Ai, Y., Hardy, P., Nelson, P.T., Guzaev, A.P., Butt, M.T. et al. (2011) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp. Neurol., 233, 463-471.
176. Grondin, R., Kaytor, M.D., Ai, Y., Nelson, P.T., Thakker, D.R., Heisel, J., Weatherspoon, M.R., Blum, J.L., Burright, E.N., Zhang, Z. et al. (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain, 135, 1197-1209.
177. Kim, D.H. and Rossi, J.J. (2003) Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev., 13, 151-155.
178. Kubodera, T., Yokota, T., Ishikawa, K. and Mizusawa, H. (2005) New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides, 15, 298-302.
179. Fiszer, A., Olejniczak, M., Switonski, P.M., Wroblewska, J.P., Wisniewska-Kruk, J., Mykowska, A. and Krzyzosiak, W.J. (2012) An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. BMC Mol. Biol., 13, doi:10.1186/1471-2199-13-6.
180. O'Reilly, M., Palfi, A., Chadderton, N., Millington-Ward, S., Ader, M., Cronin, T., Tuohy, T., Auricchio, A., Hildinger, M., Tivnan, A. et al. (2007) RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am. J. Hum. Genet., 81, 127-135.
181. Du, Q., Thonberg, H., Wang, J., Wahlestedt, C. and Liang, Z. (2005) A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res., 33, 1671-1677.
182. Huang, H., Qiao, R., Zhao, D., Zhang, T., Li, Y., Yi, F., Lai, F., Hong, J., Ding, X., Yang, Z. et al. (2009) Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res., 37, 7560-7569.
183. Miller, V.M., Xia, H., Marrs, G.L., Gouvion, C.M., Lee, G., Davidson, B.L. and Paulson, H.L. (2003) Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. U.S.A., 100, 7195-7200.
184. Li, Y., Yokota, T., Matsumura, R., Taira, K. and Mizusawa, H. (2004) Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA. Ann. Neurol., 56, 124-129.
185. Gaspar, C., Lopes-Cendes, I., Hayes, S., Goto, J., Arvidsson, K., Dias, A., Silveira, I., Maciel, P., Coutinho, P., Lima, M. et al. (2001) Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am. J. Hum. Genet., 68, 523-528.
186. Alves, S., Nascimento-Ferreira, I., Auregan, G., Hassig, R., Dufour, N., Brouillet, E., Pedroso de Lima, M.C., Hantraye, P., Pereira de Almeida, L. and Deglon, N. (2008) Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One, 3, e3341.
187. Ńobrega, C., Nascimento-Ferreira, I., Onofre, I., Albuquerque, D., Hirai, H., D́eglon, N. and de Almeida, L.P. (2013) Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS One, 8, e52396.
188. Scholefield, J., Greenberg, L.J., Weinberg, M.S., Arbuthnot, P.B., Abdelgany, A. and Wood, M.J. (2009) Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One, 4, e7232.
189. Warby, S.C., Montpetit, A., Hayden, A.R., Carroll, J.B., Butland, S.L., Visscher, H., Collins, J.A., Semaka, A., Hudson, T.J. and Hayden, M.R. (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am. J. Hum. Genet., 84, 351-366.
190. Schwarz, D.S., Ding, H., Kennington, L., Moore, J.T., Schelter, J., Burchard, J., Linsley, P.S., Aronin, N., Xu, Z. and Zamore, P.D. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet., 2, e140.
191. Van Bilsen, P.H., Jaspers, L., Lombardi, M.S., Odekerken, J.C., Burright, E.N. and Kaemmerer, W.F. (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene Ther., 19, 710-719.
192. Lombardi, M.S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Di Maria, E., Donato, S.D. and Kaemmerer, W.F. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol., 217, 312-319.
193. Pfister, E.L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.P., Zamore, P.D. and Aronin, N. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol., 19, 774-778.
194. Takahashi, M., Watanabe, S., Murata, M., Furuya, H., Kanazawa, I., Wada, K. and Hohjoh, H. (2010) Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc. Natl. Acad. Sci. U.S.A., 107, 21731-21736.
195. Carroll, J.B., Warby, S.C., Southwell, A.L., Doty, C.N., Greenlee, S., Skotte, N., Hung, G., Bennett, C.F., Freier, S.M. and Hayden, M.R. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther., 19, 2178-2185.
196. Ostergaard, M.E., Southwell, A.L., Kordasiewicz, H., Watt, A.T., Skotte, N.H., Doty, C.N., Vaid, K., Villanueva, E.B., Swayze, E.E., Frank Bennett, C. et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res., 41, 9634-9650.
197. Southwell, A.L., Warby, S.C., Carroll, J.B., Doty, C.N., Skotte, N.H., Zhang, W., Villanueva, E.B., Kovalik, V., Xie, Y., Pouladi, M.A. et al. (2013) A fully humanized transgenic mouse model of Huntington disease. Hum. Mol. Genet., 22, 18-34.
198. Kozlowski, P., de Mezer, M. and Krzyzosiak, W.J. (2010) Trinucleotide repeats in human genome and exome. Nucleic Acids Res., 38, 4027-4039.
199. Hu, J., Liu, J. and Corey, D.R. (2010) Allele-selective inhibition of Huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol., 17, 1183-1188.
200. Fiszer, A., Mykowska, A. and Krzyzosiak, W.J. (2011) Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res., 39, 5578-5585.
201. Hu, J., Matsui, M., Gagnon, K.T., Schwartz, J.C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I. and Corey, D.R. (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol., 27, 478-484.
202. Gagnon, K.T., Pendergraff, H.M., Deleavey, G.F., Swayze, E.E., Potier, P., Randolph, J., Roesch, E.B., Chattopadhyaya, J., Damha, M.J., Bennett, C.F. et al. (2010) Allele-selective inhibition of mutant Huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry, 49, 10166-10178.
203. Hu, J., Liu, J., Yu, D., Chu, Y. and Corey, D.R. (2012) Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway. Nucleic Acids Res., 40, 11270-11280.
204. Hu, J., Gagnon, K.T., Liu, J., Watts, J.K., Syeda-Nawaz, J., Bennett, C.F., Swayze, E.E., Randolph, J., Chattopadhyaya, J. and Corey, D.R. (2011) Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol. Chem., 392, 315-325.
205. Lima, W.F., Prakash, T.P., Murray, H.M., Kinberger, G.A., Li, W., Chappell, A.E., Li, C.S., Murray, S.F., Gaus, H., Seth, P.P. et al. (2012) Single-stranded siRNAs activate RNAi in animals. Cell, 150, 883-894.
206. Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H.B., Cleveland, D.W., Swayze, E.E., Lima, W.F., Crooke, S.T., Prakash, T.P. and Corey, D.R. (2012) Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell, 150, 895-908.
207. Liu, J., Yu, D., Aiba, Y., Pendergraff, H., Swayze, E.E., Lima, W.F., Hu, J., Prakash, T.P. and Corey, D.R. (2013) ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. Nucleic Acids Res., 41, 9570-9583.
208. Fiszer, A., Olejniczak, M., Galka-Marciniak, P., Mykowska, A. and Krzyzosiak, W.J. (2013) Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. Nucleic Acids Res., 41, 10426-10437.
209. Krzyzosiak, W.J., Sobczak, K., Wojciechowska, M., Fiszer, A., Mykowska, A. and Kozlowski, P. (2012) Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res., 40, 11-26.
210. Sathasivam, K., Woodman, B., Mahal, a, Bertaux, F., Wanker, E.E., Shima, D.T. and Bates, G.P. (2001) Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Hum. Mol. Genet., 10, 2425-2435.
211. Marchina, E., Misasi, S., Bozzato, A., Ferraboli, S., Agosti, C., Rozzini, L., Borsani, G., Barlati, S. and Padovani, A. (2014) Gene expression profile in fibroblasts of Huntington's disease patients and controls. J. Neurol. Sci., 337, 42-46.
212. Koch, P., Breuer, P., Peitz, M., Jungverdorben, J., Kesavan, J., Poppe, D., Doerr, J., Ladewig, J., Mertens, J., Tuting, T. et al. (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature, 480, 543-546.
213. Consortium (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell, 11, 264-278.
214. Zhang, N., An, M.C., Montoro, D. and Ellerby, L.M. (2010) Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr., 2, RRN1193.
215. Camnasio, S., Delli Carri, A., Lombardo, A., Grad, I., Mariotti, C., Castucci, A., Rozell, B., Lo Riso, P., Castiglioni, V., Zuccato, C. et al. (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol. Dis., 46, 41-51.
216. Jeon, I., Lee, N., Li, J.-Y., Park, I.-H., Park, K.S., Moon, J., Shim, S.H., Choi, C., Chang, D.-J., Kwon, J. et al. (2012) Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells, 30, 2054-2062.
217. Chae, J.-I., Kim, D.-W., Lee, N., Jeon, Y.-J., Jeon, I., Kwon, J., Kim, J., Soh, Y., Lee, D.-S., Seo, K.S. et al. (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem. J., 446, 359-371.
218. Nihei, Y., Ito, D., Okada, Y., Akamatsu, W., Yagi, T., Yoshizaki, T., Okano, H. and Suzuki, N. (2013) Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy. J. Biol. Chem., 288, 8043-8052.
219. Xia, G., Santostefano, K., Hamazaki, T., Liu, J., Subramony, S.H., Terada, N. and Ashizawa, T. (2013) Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 in vitro. J. Mol. Neurosci., 51, 237-248.
220. An, M.C., Zhang, N., Scott, G., Montoro, D., Wittkop, T., Mooney, S., Melov, S. and Ellerby, L.M. (2012) Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell, 11, 253-263.
221. Kaye, J.A. and Finkbeiner, S. (2013) Modeling Huntington's disease with induced pluripotent stem cells. Mol. Cell. Neurosci., 56, 50-64.
222. Gao, A., Peng, Y., Deng, Y. and Qing, H. (2013) Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases. Neuroscience, 228, 47-59.
223. Crook, Z.R. and Housman, D. (2011) Huntington's disease: can mice lead the way to treatment Neuron, 69, 423-435.
224. Figiel, M., Szlachcic, W.J., Switonski, P.M., Gabka, A. and Krzyzosiak, W.J. (2012) Mouse models of polyglutamine diseases: review and data table. Part I. Mol. Neurobiol., 46, 393-429.
225. Yang, S.-H., Cheng, P.-H., Banta, H., Piotrowska-Nitsche, K., Yang, J.-J., Cheng, E.C.H., Snyder, B., Larkin, K., Liu, J., Orkin, J. et al. (2008) Towards a transgenic model of Huntington's disease in a non-human primate. Nature, 453, 921-924.
226. Jacobsen, J.C., Bawden, C.S., Rudiger, S.R., McLaughlan, C.J., Reid, S.J., Waldvogel, H.J., MacDonald, M.E., Gusella, J.F., Walker, S.K., Kelly, J.M. et al. (2010) An ovine transgenic Huntington's disease model. Hum. Mol. Genet., 19, 1873-1882.
227. Yang, D., Wang, C.-E., Zhao, B., Li, W., Ouyang, Z., Liu, Z., Yang, H., Fan, P., O'Neill, A., Gu, W. et al. (2010) Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum. Mol. Genet., 19, 3983-3994.
228. Sciabola, S., Cao, Q., Orozco, M., Faustino, I. and Stanton, R. V (2013) Improved nucleic acid descriptors for siRNA efficacy prediction. Nucleic Acids Res., 41, 1383-1394.
229. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W.S. and Khvorova, A. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol., 22, 326-330.
230. Matveeva, O., Nechipurenko, Y., Rossi, L., Moore, B., Saetrom, P., Ogurtsov, A.Y., Atkins, J.F. and Shabalina, S.A. (2007) Comparison of approaches for rational siRNA design leading to a new efficient and transparent method. Nucleic Acids Res., 35, e63.
231. Patrick Walton, S., Wu, M., Gredell, J.A. and Chan, C. (2010) Designing highly active siRNAs for therapeutic applications. FEBS J., 277, 4806-4813.
232. Patzel, V., Rutz, S., Dietrich, I., Koberle, C., Scheffold, A. and Kaufmann, S.H. (2005) Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat. Biotechnol., 23, 1440-1444.
233. Westerhout, E.M. and Berkhout, B. (2007) A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res., 35, 4322-4330.
234. Tafer, H., Ameres, S.L., Obernosterer, G., Gebeshuber, C.A., Schroeder, R., Martinez, J. and Hofacker, I.L. (2008) The impact of target site accessibility on the design of effective siRNAs. Nat. Biotechnol., 26, 578-583.
235. Gredell, J.A., Berger, A.K. and Walton, S.P. (2008) Impact of target mRNA structure on siRNA silencing efficiency: a large-scale study. Biotechnol. Bioeng., 100, 744-755.
236. Kretschmer-Kazemi Far, R. and Sczakiel, G. (2003) The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res., 31, 4417-4424.
237. Crooke, S.T., Vickers, T.A., Lima, W.F. and Wu, H. (2008) Mechanisms of antisense drug action, an introduction. In: Crooke ST (ed.) Antisense Drug Technology: Principles, Strategies, and Applications. CRC Press, Boca Raton, pp. 3-46.
238. Geary, R.S., Yu, R.Z. and Levin, A.A. (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. Drugs, 2, 562-573.
239. Henry, S.P., Geary, R.S., Yu, R. and Levin, A.A. (2001) Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors Curr. Opin. Investig. Drugs, 2, 1444-1449.
240. Sipa, K., Sochacka, E., Kazmierczak-Baranska, J., Maszewska, M., Janicka, M., Nowak, G. and Nawrot, B. (2007) Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA, 13, 1301-1316.
241. Bramsen, J.B., Laursen, M.B., Nielsen, A.F., Hansen, T.B., Bus, C., Langkjaer, N., Babu, B.R., Hojland, T., Abramov, M., Van Aerschot, A. et al. (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res., 37, 2867-2881.
242. Engels, J.W. (2013) Gene silencing by chemically modified siRNAs. New Biotechnol., 30, 302-307.
243. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595-605.
244. McManus, M.T., Petersen, C.P., Haines, B.B., Chen, J. and Sharp, P.A. (2002) Gene silencing using micro-RNA designed hairpins. RNA, 8, 842-850.
245. Paddison, P.J., Caudy, A.A., Bernstein, E., Hannon, G.J. and Conklin, D.S. (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev., 16, 948-958.
246. Boudreau, R.L., Monteys, A.M. and Davidson, B.L. (2008) Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA, 14, 1834-1844.
247. McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A.M., Martins, I., Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B. et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U.S.A., 105, 5868-5873.
248. Doench, J.G. and Sharp, P.A. (2004) Specificity of microRNA target selection in translational repression. Genes Dev., 18, 504-511.
249. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
250. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S. V, Burchard, J., Mao, M., Li, B., Cavet, G. and Linsley, P.S. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635-637.
251. Boudreau, R.L., Spengler, R.M. and Davidson, B.L. (2011) Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol. Ther., 19, 2169-2177.
252. Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J.M., Lim, L., Karpilow, J., Nichols, K. et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA, 12, 1197-1205.
253. Sioud, M. (2009) Deciphering the code of innate immunity recognition of siRNAs. Methods Mol. Biol., 487, 41-59.
254. Sun, X., Rogoff, H.A. and Li, C.J. (2008) Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat. Biotechnol., 26, 1379-1382.
255. Chang, C.I., Yoo, J.W., Hong, S.W., Lee, S.E., Kang, H.S., Sun, X., Rogoff, H.A., Ban, C., Kim, S., Li, C.J. et al. (2009) Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol. Ther., 17, 725-732.
256. Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R., Marion, P., Salazar, F. and Kay, M.A. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441, 537-41.
257. Khan, A.A., Betel, D., Miller, M.L., Sander, C., Leslie, C.S. and Marks, D.S. (2009) Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol., 27, 549-555.
258. Olejniczak, M., Galka, P. and Krzyzosiak, W.J. (2010) Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res., 38, 1-16.
259. Dirin, M. and Winkler, J. (2013) Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin. Biol. Ther., 13, 875-88.
260. Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A. et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med., 11, 263-270.
261. Judge, A.D., Sood, V., Shaw, J.R., Fang, D., McClintock, K. and MacLachlan, I. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol., 23, 457-462.
262. Fedorov, Y., Anderson, E.M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W.S. and Khvorova, A. (2006) Off-target effects by siRNA can induce toxic phenotype. RNA, 12, 1188-1196.
263. Olejniczak, M., Galka-Marciniak, P., Polak, K., Fligier, A. and Krzyzosiak, W.J. (2012) RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents. RNA, 18, 930-935.
264. Sioud, M. (2007) RNA interference and innate immunity. Adv. Drug Deliv. Rev., 59, 153-163.
265. Judge, A. and MacLachlan, I. (2008) Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther., 19, 111-124.
266. Olejniczak, M., Polak, K., Galka-Marciniak, P. and Krzyzosiak, W.J. (2011) Recent advances in understanding of the immunological off-target effects of siRNA. Curr. Gene Ther., 11, 532-543.
267. Samaranch, L., Salegio, E.A., San Sebastian, W., Kells, A.P., Foust, K.D., Bringas, J.R., Lamarre, C., Forsayeth, J., Kaspar, B.K. and Bankiewicz, K.S. (2012) Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gen. Ther., 23, 382-389.
268. Kenny, G.D., Bienemann, A.S., Tagalakis, A.D., Pugh, J.A., Welser, K., Campbell, F., Tabor, A.B., Hailes, H.C., Gill, S.S., Lythgoe, M.F. et al. (2013) Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the brain. Biomaterials, 34, 9190-9200.
269. San Sebastian, W., Samaranch, L., Kells, A.P., Forsayeth, J. and Bankiewicz, K.S. (2013) Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics, 10, 498-510.
270. Juliano, R., Alam, M.R., Dixit, V. and Kang, H. (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 36, 4158-4171.
271. White, P.J., Anastasopoulos, F., Pouton, C.W. and Boyd, B.J. (2009) Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides. Expert Rev. Mol. Med., 11, e10.
272. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S. and Wood, M.J.A. (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol., 29, 341-345.
273. El Andaloussi, S., Lakhal, S., M̈ager, I. and Wood, M.J.A. (2013) Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev., 65, 391-397.
274. Dufour, B.D., Smith, C.A., Clark, R.L., Walker, T. and McBride, J.L. (2014) Intra-jugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol. Ther., 10.1038/mt.2013.289.
275. Weir, D.W., Sturrock, A. and Leavitt, B.R. (2011) Development of biomarkers for Huntington's disease. Lancet Neurol., 10, 573-590.
276. Georgiou-Karistianis, N., Scahill, R., Tabrizi, S.J., Squitieri, F. and Aylward, E. (2013) Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci. Biobehav. Rev., 37, 480-490.
277. Strand, A.D., Aragaki, A.K., Shaw, D., Bird, T., Holton, J., Turner, C., Tapscott, S.J., Tabrizi, S.J., Schapira, A.H., Kooperberg, C. et al. (2005) Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum. Mol. Genet., 14, 1863-1876.
278. Anderson, A.N., Roncaroli, F., Hodges, A., Deprez, M. and Turkheimer, F.E. (2008) Chromosomal profiles of gene expression in Huntington's disease. Brain, 131, 381-388.
279. Sassone, J., Colciago, C., Cislaghi, G., Silani, V. and Ciammola, A. (2009) Huntington's disease: the current state of research with peripheral tissues. Exp. Neurol., 219, 385-397.
280. Bradford, J.W., Li, S. and Li, X.-J. (2010) Polyglutamine toxicity in non-neuronal cells. Cell Res., 20, 400-407.
281. Diamanti, D., Mori, E., Incarnato, D., Malusa, F., Fondelli, C., Magnoni, L. and Pollio, G. (2013) Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model. Biomark. Res., 1, doi:10.1186/2050-7771-1-28.
282. Tr̈ager, U., Andre, R., Lahiri, N., Magnusson-Lind, A., Weiss, A., Grueninger, S., McKinnon, C., Sirinathsinghji, E., Kahlon, S., Pfister, E.L. et al. (2014) HTT-lowering reverses Huntington's disease immune dysfunction caused by NF-B pathway dysregulation. Brain, 137, 819-833.
283. Boy, J., Schmidt, T., Wolburg, H., Mack, A., Nuber, S., B̈ottcher, M., Schmitt, I., Holzmann, C., Zimmermann, F., Servadio, A. et al. (2009) Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum. Mol. Genet., 18, 4282-4295.
284. Furrer, S.A., Waldherr, S.M., Mohanachandran, M.S., Baughn, T.D., Nguyen, K.-T., Sopher, B.L., Damian, V.A., Garden, G.A. and La Spada, A.R. (2013) Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7. Hum. Mol. Genet., 22, 890-903.
285. Lu, X.-H. and Yang, X.W. (2012) "Huntingtin holiday": progress toward an antisense therapy for Huntington's disease. Neuron, 74, 964-966.
286. Corey, D.R. (2007) RNA learns from antisense. Nat. Chem. Biol., 3, 8-11.
287. Levin, A.A., Yu, R.Z. and Geary, R.S. (2008) Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke ST (ed). Antisense Drug Technology: Principles, Strategies, and Applications. CRC Press, Boca Raton , pp. 183-215.
288. Koide, R., Ikeuchi, T., Onodera, O., Tanaka, H., Igarashi, S., Endo, K., Takahashi, H., Kondo, R., Ishikawa, A., Hayashi, T. et al. (1994) Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat. Genet., 6, 9-13.
289. Nagafuchi, S., Yanagisawa, H., Sato, K., Shirayama, T., Ohsaki, E., Bundo, M., Takeda, T., Tadokoro, K., Kondo, I., Murayama, N. et al. (1994) Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat. Genet., 6, 14-18.
290. MacDonald, M.E., Ambrose, C.M. and Duyao, M.P. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
291. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. and Fischbeck, K.H. (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature, 352, 77-79.
292. Orr, H.T., Chung, M.Y., Banfi, S., Kwiatkowski, T.J. Jr, Servadio, A., Beaudet, A.L., McCall, A.E., Duvick, L.A., Ranum, L.P. and Zoghbi, H.Y. (1993) Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet., 4, 221-226.
293. Imbert, G., Saudou, F., Yvert, G., Devys, D., Trottier, Y., Garnier, J.M., Weber, C., Mandel, J.L., Cancel, G., Abbas, N. et al. (1996) Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet., 14, 285-291.
294. Pulst, S.M., Nechiporuk, A., Nechiporuk, T., Gispert, S., Chen, X.N., Lopes-Cendes, I., Pearlman, S., Starkman, S., Orozco-Diaz, G., Lunkes, A. et al. (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet., 14, 269-276.
295. Sanpei, K., Takano, H., Igarashi, S., Sato, T., Oyake, M., Sasaki, H., Wakisaka, A., Tashiro, K., Ishida, Y., Ikeuchi, T. et al. (1996) Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat. Genet., 14, 277-284.
296. Kawaguchi, Y., Okamoto, T., Taniwaki, M., Aizawa, M., Inoue, M., Katayama, S., Kawakami, H., Nakamura, S., Nishimura, M., Akiguchi, I. et al. (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet., 8, 221-228.
297. Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D.W., Amos, C., Dobyns, W.B., Subramony, S.H., Zoghbi, H.Y. and Lee, C.C. (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet., 15, 62-69.
298. David, G., Abbas, N., Stevanin, G., Durr, A., Yvert, G., Cancel, G., Weber, C., Imbert, G., Saudou, F., Antoniou, E. et al. (1997) Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat. Genet., 17, 65-70.
299. Koide, R., Kobayashi, S., Shimohata, T., Ikeuchi, T., Maruyama, M., Saito, M., Yamada, M., Takahashi, H. and Tsuji, S. (1999) A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease Hum. Mol. Genet., 8, 2047-2053.
300. Nakamura, K., Jeong, S.Y., Uchihara, T., Anno, M., Nagashima, K., Nagashima, T., Ikeda, S., Tsuji, S. and Kanazawa, I. (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet., 10, 1441-1448.
301. Zhang, Y., Engelman, J. and Friedlander, R.M. (2009) Allele-specific silencing of mutant Huntington's disease gene. J. Neurochem., 108, 82-90.
302. Caplen, N.J., Taylor, J.P., Statham, V.S., Tanaka, F., Fire, A. and Morgan, R.A. (2002) Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum. Mol. Genet., 11, 175-184.
303. Hu, J., Matsui, M. and Corey, D.R. (2009) Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic
304. Gagnon, K.T., Watts, J.K., Pendergraff, H.M., Montaillier, C., Thai, D., Potier, P. and Corey, D.R. (2011) Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates. J. Am. Chem. Soc., 133, 8404-8407.
305. Liu, J., Pendergraff, H., Narayanannair, K.J., Lackey, J.G., Kuchimanchi, S., Rajeev, K.G., Manoharan, M., Hu, J. and Corey, D.R. (2013) RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucleic Acids Res., 41, 8788-8801.
306. Aiba, Y., Hu, J., Liu, J., Xiang, Q., Martinez, C. and Corey, D.R. (2013) Allele-selective inhibition of Huntingtin and Ataxin-3 expression by RNA duplexes containing unlocked nucleic acid (UNA) substitutions. Biochemistry, 52, 9329-9338.